KR20240169002A - 이미다조[4,5-b]피리딘 유도체에 의한 고형암 치료를 위한 바이오마커 - Google Patents

이미다조[4,5-b]피리딘 유도체에 의한 고형암 치료를 위한 바이오마커 Download PDF

Info

Publication number
KR20240169002A
KR20240169002A KR1020247034361A KR20247034361A KR20240169002A KR 20240169002 A KR20240169002 A KR 20240169002A KR 1020247034361 A KR1020247034361 A KR 1020247034361A KR 20247034361 A KR20247034361 A KR 20247034361A KR 20240169002 A KR20240169002 A KR 20240169002A
Authority
KR
South Korea
Prior art keywords
cancer
gene
myc
mutation
myc gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034361A
Other languages
English (en)
Korean (ko)
Inventor
히로카즈 도자키
다이스케 모리시타
아키오 미즈타니
요시히코 사토
고키 히카미
히로유키 마노
신지 고사카
아키노부 하마다
시게히로 야기시타
겐이치 이와이
마사히로 야구치
가즈호 구마자와
도시유키 노무라
Original Assignee
코디아 세라퓨틱스 가부시키가이샤
국립연구개발법인 고쿠리츠간켄큐센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코디아 세라퓨틱스 가부시키가이샤, 국립연구개발법인 고쿠리츠간켄큐센터 filed Critical 코디아 세라퓨틱스 가부시키가이샤
Publication of KR20240169002A publication Critical patent/KR20240169002A/ko
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/574—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247034361A 2022-03-31 2023-03-30 이미다조[4,5-b]피리딘 유도체에 의한 고형암 치료를 위한 바이오마커 Pending KR20240169002A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022060240 2022-03-31
JPJP-P-2022-060240 2022-03-31
PCT/JP2023/013361 WO2023190967A1 (ja) 2022-03-31 2023-03-30 イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー

Publications (1)

Publication Number Publication Date
KR20240169002A true KR20240169002A (ko) 2024-12-02

Family

ID=88202235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034361A Pending KR20240169002A (ko) 2022-03-31 2023-03-30 이미다조[4,5-b]피리딘 유도체에 의한 고형암 치료를 위한 바이오마커

Country Status (7)

Country Link
US (1) US20260108526A1 (https=)
EP (1) EP4501328A4 (https=)
JP (1) JPWO2023190967A1 (https=)
KR (1) KR20240169002A (https=)
CN (1) CN119053329A (https=)
CA (1) CA3246851A1 (https=)
WO (1) WO2023190967A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025150571A1 (ja) * 2024-01-12 2025-07-17 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 Ｃｌｋ阻害剤を有効成分として含むがん治療剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017188374A1 (ja) 2016-04-28 2017-11-02 武田薬品工業株式会社 縮合複素環化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
MX2010005960A (es) * 2007-11-30 2010-06-11 Schering Corp Biomarcadores de braf.
US11946934B2 (en) * 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
JP7224645B2 (ja) 2017-03-30 2023-02-20 国立大学法人 東京大学 異なる複数の目的遺伝子の評価方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017188374A1 (ja) 2016-04-28 2017-11-02 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
EP4501328A1 (en) 2025-02-05
WO2023190967A1 (ja) 2023-10-05
JPWO2023190967A1 (https=) 2023-10-05
CA3246851A1 (en) 2025-02-03
CN119053329A (zh) 2024-11-29
US20260108526A1 (en) 2026-04-23
EP4501328A4 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
Bardelli et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
JP7044746B2 (ja) 癌治療に対する感受性を予測するためのバイオマーカー
US20130217721A1 (en) Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
ES2622401T3 (es) Método de predicción de la eficacia de un inhibidor de la angiogénesis
TWI838345B (zh) 外顯子18及/或外顯子21突變型egfr之選擇性抑制劑
JP2013543008A (ja) Ｂｒａｆ阻害剤による治療方法
CN104169425A (zh) 前列腺癌细胞系、遗传标志及其用途
EP3102705A2 (en) Method of identifying tyrosine kinase receptor rearrangements in patients
Zangari et al. Genetics of bladder malignant tumors in childhood
TWI550089B (zh) Evaluation of anti-tumor agents and therapeutic effects in patients with mutated colorectal cancer of KRAS gene
KR20240169002A (ko) 이미다조[4,5-b]피리딘 유도체에 의한 고형암 치료를 위한 바이오마커
ES3054788T3 (en) Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors
Komuro et al. Identification of a novel fusion gene HMGA2‐EGFR in glioblastoma
WO2006073202A9 (ja) GSK3β阻害効果に基づくがんの抑制および抗がん剤の評価方法
Ritu et al. Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
JP7747459B2 (ja) Ｆｇｆｒ阻害薬に対する感受性の判定方法
HK40112492A (zh) 利用咪唑并[4，5-b]吡啶衍生物治疗实体瘤的生物标志物
US20230042367A1 (en) Methods and compositions for treating cancers having f-box and wd-repeat protein 7 (fbxw7) alterations and/or cyclin l1 (ccnl1) gain or amplification
Mondal et al. KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways. Cells 2024, 13, 1221. h ps
Ulivi et al. Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects
Deenichina Investigating the role of FOSL1/FRA1 in BRAF-V600E patient-derived colorectal cancer organoids
WO2022013328A1 (en) Method for determining sensitivity to an antineoplastic agent
Al-Khafaji Investigation of molecular modulation of taxane response in respiratory tract cancers by differential expression of mitotic spindle associated genes
JP2009011249A (ja) 胃を原発巣とする消化管間質腫瘍の悪性化の診断法
WO2020079433A1 (en) Target for anti-cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201